by Internet Medical Society
The FDA approved the drug Erlotinib for treating patients who have locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic pancreatic cancer. This drug is sold under the trade name Tarceva. Erlotinib is supplied in 100 mg and 150 mg to administer orally via the mouth. Erlotinib reversibly inhibits the kinase activity of EGFR, preventing autophosphorylation of tyrosine residues associated with the receptor and thereby inhibiting further downstream signaling. The common side-effects of Erlotinib are fatigue, loss of appetite, partial hair loss, diarrhea, mouth sores, vomiting, rashes, weight loss, dry skin, eye irritation, weight decrease, infection, edema, pyrexia, constipation, bone pain, dyspnea, stomatitis, and myalgia.
Tarceva 150 mg and 100 mg are available from multiple generic medicine suppliers. For the best buy, please ring us on toll-free no. 18008891064.